Patent ID: 11919959
Assignee: CANCER RESEARCH TECHNOLOGY LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 0:
1. A method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2, wherein the agent is an antibody, or an antigen-binding fragment thereof, which selectively binds CLEC14A and comprises:
(i) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 47; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 48; or

(ii) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 2 or SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 3; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6; or

(iii) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 42; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 44; or

(iv) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 77; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6; or

(v) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 45; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 44; or

(vi) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 46; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6.